IMPACT OF NEXTSENSE INSTITUTE RESEARCH IN THE FIELD OF SENSORY DISABILITIES
With
Professor Greg Leigh AO,
Director, NextSense Institute, Australia &
Conjoint Professor,
Macquarie School of Education
Macquarie University, Sydney
RESEARCH IMPACT
Filmed in Sydney, Australia | June 2025
NextSense, formerly known as the Royal Institute for Deaf & Blind Children, is a not-for-profit established in 1860 that provides dedicated, innovative, and customised services aimed at breaking down barriers for children, adults and families of people with hearing or vision loss.
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations.
The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
The Institute offers a range of educational programs, including postgraduate degrees, professional development courses, and customised training for educators, therapists, health professionals, and carers. One of its flagship programs is the Master of Disability Studies, delivered in affiliation with Macquarie University, which prepares professionals to work with individuals who are deaf, hard of hearing, blind, or have low vision.
Professor Greg Leigh AO, Director NextSense Institute, talks about 3 areas of research that have had significant impact in it’s delivery of programs and services to Australians and countries across the world.
Through this research, NextSense Institute aims to break down barriers and redefine what is possible for individuals with sensory disabilities, fostering inclusion and enhancing quality of life.
Source: Written by AUDIENCED using source information from the NextSense website
-
Liver cancer biomarkers, risk prediction & progression
Dr. Rodrigo Carlessi is an expert in Cancer Genomics and Molecular Biology, with an extensive track record in liver cancer research. He leads the Cancer Genomics Group within the Liver Disease and Regeneration Laboratory at the Curtin Medical Research Institute. He has an impressive publication record, with 43 manuscripts that have collectively garnered over 2,680 citations. His research leverages cutting-edge genomics and transcriptomics technologies, as well as long-read DNA sequencing, to explore mechanisms, identify biomarkers, and develop therapeutic targets in liver disease and cancer.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
Infections and other lung diseases using models of human lung tissue grown from stem cells
Dr Rhiannon Werder is a Team Leader at Murdoch Children’s Research Institute leading a multidisciplinary team, combining expertise in stem cell biology and immunology, to develop new therapies for lung diseases. Her research centres around induced pluripotent stem cells to investigate respiratory diseases, spanning acute respiratory infections to chronic lung diseases. Using stem cells, Dr Werder’s team creates models of human lung tissue. With these models, Dr Werder is investigating how human-specific pathogens infect different regions of the lung, the ensuing immune responses, and how the lung repairs itself after infections, especially in people with preexisting lung diseases.
